MDPI and ACS Style
Proietti, R.; Rivera-Caravaca, J.M.; López-Gálvez, R.; Harrison, S.L.; MarÃn, F.; Underhill, P.; Shantsila, E.; McDowell, G.; Vinciguerra, M.; Davies, R.;
et al. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. J. Clin. Med. 2023, 12, 2814.
https://doi.org/10.3390/jcm12082814
AMA Style
Proietti R, Rivera-Caravaca JM, López-Gálvez R, Harrison SL, MarÃn F, Underhill P, Shantsila E, McDowell G, Vinciguerra M, Davies R,
et al. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. Journal of Clinical Medicine. 2023; 12(8):2814.
https://doi.org/10.3390/jcm12082814
Chicago/Turabian Style
Proietti, Riccardo, José Miguel Rivera-Caravaca, Raquel López-Gálvez, Stephanie L. Harrison, Francisco MarÃn, Paula Underhill, Eduard Shantsila, Garry McDowell, Manlio Vinciguerra, Rhys Davies,
and et al. 2023. "Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis" Journal of Clinical Medicine 12, no. 8: 2814.
https://doi.org/10.3390/jcm12082814
